Please assess the completion status of the following clinical trial:

Trial Title: Remote Monitoring of the Diabetic Foot to Prevent Re-Ulceration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Understanding of the study procedures and conditions of the protocol and agreement to participate in the study by providing consent prior to any study-specific procedures.~2. Male or female patients 18 years or older.~3. Diagnosis of type 1 or type 2 diabetes mellitus more than 3 months prior to the Screening Visit.~4. History of healed diabetic foot ulcer(s), present for at least 2 weeks and healed within 2-24 months prior to screening.~5. Confirmation of presence of peripheral neuropathy with loss of protective sensation (documented in medical records or certain ICD-10 codes for care of patients with diabetes and loss of protective sensation)~6. Patient has signed up for and provided or will provide consent to review of medical records available via the Pluto platform.~7. Access to internet service at the site of device use or willing to use a 4G router provided by the Sponsor~8. Access to cell phone on which they can receive study communications~9. Has a healthcare provider who is confirmed to be their point of contact for foot care or injuries and this HCP uses an EHR that is compatible with Pluto~10. English speaking~Exclusion Criteria:~1. Patients with active foot ulcers or other open foot lesions~2. Weight, when fully clothed, of greater than 150 kg~3. Active Charcot arthropathy defined as the phase where the foot is undergoing collapse~4. Active foot infection or gangrene~5. Any history of major or minor lower limb amputation of more than 3 toes. NOTE: the hallux toe must be present on both feet to be eligible~6. Critical limb ischemia as evidenced by rest pain. NOTE: a healed ulcer indicates adequate perfusion and qualifies for the study~7. End-stage kidney disease (estimated GFR \<15 mL/min/1.73 m2, and/or receiving renal replacement therapy)~8. Known pregnancy at the time of enrollment.\*~9. Any mental health disorder, psychiatric disorder, or alcohol or drug abuse history such that, in the opinion of the investigator, the patient is unreliable as a study participant~10. Any travel plans expected to result in an interruption of BMS use for greater than 30 consecutive days.~11. Unable to identify and/or return to a usual care provider for foot care for the duration of the study~12. Unable or unwilling to be enrolled in the Pluto unified medical records system~13. Other issue that, at the discretion of the PI, renders the participant ineligible for participation. This includes inability to use the BMS for at least 3 days per week.~    * Participants who become pregnant during the study will not be removed. Pregnancy will be noted in their mobile application profile and their participation in the study will be closely monitored.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Use of Bluedrop Monitoring Service (Type: EXPERIMENTAL): The BMS is made up of the Delta Foot Scanner (DFS) device, its accompanying Sentinel Review Interface (SRI) software and a Bluedrop virtual monitoring service.~The DFS is intended to be used for 30 seconds, once per day, by a person in their home. It is important that while using the device that the participant continues with their routine foot care as recommended by their doctor.
- Standard of care (Type: NO_INTERVENTION): Participants continue with routine foot care as recommended by their doctor

Based on this trial design, predict the completion outcome and termination type (if applicable).